| Perispinal etanercept: a new therapeutic paradigm in neurology. | |
| | |
MedLine Citation:
|
PMID: 20518613 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Etanercept is a potent antagonist of TNF, a pleotropic immune signaling molecule that is also a pivotal regulator of synaptic function. Excess TNF is centrally involved in the pathogenesis of a variety of inflammatory neurological disorders, including Alzheimer's disease, sciatica, traumatic brain injury and spinal cord injury. Perispinal etanercept produces rapid improvement in both Alzheimer's disease and sciatica and in other forms of disc-related pain. Basic research and the observed clinical effects suggest that etanercept has the surprising ability to penetrate into the cerebrospinal fluid after perispinal administration. Perispinal administration is a novel method of delivery designed to introduce this anti-TNF molecule into the bidirectional cerebrospinal venous system and the cerebrospinal fluid to facilitate its selective delivery to either spinal structures or the brain. The scientific rationale, physiologic mechanisms, clinical effects and potential clinical indications of this therapeutic approach are the subject of this article. |
| | |
Authors:
|
Edward Tobinick |
Related Documents
:
|
18567623 - Debris clearance by microglia: an essential link between degeneration and regeneration. 15371513 - Tlx, an orphan nuclear receptor, regulates cell numbers and astrocyte development in th... 22166983 - B-cell maturation antigen (bcma) activation exerts specific proinflammatory effects in ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of neurotherapeutics Volume: 10 ISSN: 1744-8360 ISO Abbreviation: Expert Rev Neurother Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-03 Completed Date: 2010-08-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101129944 Medline TA: Expert Rev Neurother Country: England |
Other Details:
|
Languages: eng Pagination: 985-1002 Citation Subset: IM |
Affiliation:
|
David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suites 205-210, Los Angeles, CA 90095, USA. etmd@ucla.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Central Nervous System Diseases
/
drug therapy* Immunoglobulin G / therapeutic use* Inflammation / drug therapy* Injections, Spinal Receptors, Tumor Necrosis Factor / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein |
| Comments/Corrections | |
Erratum In:
|
Expert Rev Neurother. 2010 Jul;10(7):1232 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Voxel-based morphometry and epilepsy.
Next Document: Acknowledgements.